|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/44 | |
| A61P 35/00 | |||
| A61P 35/02 | |||
| A61K 38/18 | |||
| A61K 9/00 | |||
| A61K 31/4745 | |||
| A61K 31/555 | |||
| A61K 31/4375 | |||
| A61K 31/7068 | |||
| A61K 41/00 | |||
| A61K 45/06 | |||
| A61K 47/12 | |||
| C07D 471/04 |
| (11) | Number of the document | 2295056 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10177951.0 |
| Date of filing the European patent application | 2005-03-14 | |
| (97) | Date of publication of the European application | 2011-03-16 |
| (45) | Date of publication and mention of the grant of the patent | 2016-01-06 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 553578 P | 2004-03-15 | US |
| (72) |
Adelman, Daniel, C., US
Silverman, Jeffrey A., US
MASARU, Higaki, JP
SATOSHI, Nakao, JP
|
| (73) |
Sunesis Pharmaceuticals, Inc.,
395 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080,
US
Sumitomo Dainippon Pharma Co., Ltd., 6-8, Dosho-machi 2-chome Chuo-ku, Osaka-shi Osaka 541-8524, JP |
| (54) | Use of SNS-595 for treating leukemia |
| Use of SNS-595 for treating leukemia |